Anti-CE295/ CEP295/ KIAA1731 monoclonal antibody

Anti-CE295/ CEP295/ KIAA1731 antibody for FACS & in-vivo assay

Target products collectionGo to CEP295/CEP295 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2050-Ab-1/ GM-Tg-hg-MP2050-Ab-2Anti-Human CEP295 monoclonal antibodyHuman
GM-Tg-rg-MP2050-Ab-1/ GM-Tg-rg-MP2050-Ab-2Anti-Rat CEP295 monoclonal antibodyRat
GM-Tg-mg-MP2050-Ab-1/ GM-Tg-mg-MP2050-Ab-2Anti-Mouse CEP295 monoclonal antibodyMouse
GM-Tg-cynog-MP2050-Ab-1/ GM-Tg-cynog-MP2050-Ab-2Anti-Cynomolgus/ Rhesus macaque CEP295 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2050-Ab-1/ GM-Tg-felg-MP2050-Ab-2Anti-Feline CEP295 monoclonal antibodyFeline
GM-Tg-cang-MP2050-Ab-1/ GM-Tg-cang-MP2050-Ab-2Anti-Canine CEP295 monoclonal antibodyCanine
GM-Tg-bovg-MP2050-Ab-1/ GM-Tg-bovg-MP2050-Ab-2Anti-Bovine CEP295 monoclonal antibodyBovine
GM-Tg-equg-MP2050-Ab-1/ GM-Tg-equg-MP2050-Ab-2Anti-Equine CEP295 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2050-Ab-1/ GM-Tg-hg-MP2050-Ab-2; GM-Tg-rg-MP2050-Ab-1/ GM-Tg-rg-MP2050-Ab-2;
GM-Tg-mg-MP2050-Ab-1/ GM-Tg-mg-MP2050-Ab-2; GM-Tg-cynog-MP2050-Ab-1/ GM-Tg-cynog-MP2050-Ab-2;
GM-Tg-felg-MP2050-Ab-1/ GM-Tg-felg-MP2050-Ab-2; GM-Tg-cang-MP2050-Ab-1/ GM-Tg-cang-MP2050-Ab-2;
GM-Tg-bovg-MP2050-Ab-1/ GM-Tg-bovg-MP2050-Ab-2; GM-Tg-equg-MP2050-Ab-1/ GM-Tg-equg-MP2050-Ab-2
Products NameAnti-CEP295 monoclonal antibody
Formatmab
Target NameCEP295
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CEP295 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CE295/ CEP295/ KIAA1731 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2050
    Target NameCEP295
    Gene ID85459,319675,363018,697392,100683524,101083200,532848,100058546
    Gene Symbol and Synonyms5830418K08Rik,5832426L23Rik,CEP295,Gm1131,KIAA1731,RGD1311723
    Uniprot AccessionQ9C0D2,A4L9P8
    Uniprot Entry NameCE295_HUMAN,CE295_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000166004
    Target ClassificationN/A

    The target: CEP295, gene name: CEP295, also named as KIAA1731. Enables microtubule binding activity. Involved in several processes, including centriole replication; positive regulation of protein acetylation; and regulation of centrosome duplication. Located in cytosol; microtubule cytoskeleton; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.